These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 26846540)

  • 1. Circular RNA in blood corpuscles combined with plasma protein factor for early prediction of pre-eclampsia.
    Zhang YG; Yang HL; Long Y; Li WL
    BJOG; 2016 Dec; 123(13):2113-2118. PubMed ID: 26846540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CircRNA-0004904, CircRNA-0001855, and PAPP-A: Potential Novel Biomarkers for the Prediction of Preeclampsia.
    Jiang M; Lash GE; Zhao X; Long Y; Guo C; Yang H
    Cell Physiol Biochem; 2018; 46(6):2576-2586. PubMed ID: 29758559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of pre-eclampsia by an analysis of placenta-derived cellular mRNA in the blood of pregnant women at 15-20 weeks of gestation.
    Sekizawa A; Purwosunu Y; Farina A; Shimizu H; Nakamura M; Wibowo N; Rizzo N; Okai T
    BJOG; 2010 Apr; 117(5):557-64. PubMed ID: 20121832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.
    Chaiworapongsa T; Romero R; Whitten AE; Korzeniewski SJ; Chaemsaithong P; Hernandez-Andrade E; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2016; 29(8):1214-28. PubMed ID: 26303962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenic imbalance and plasma lipid alterations in women with preeclampsia from a developing country.
    Reyes LM; García RG; Ruiz SL; Broadhurst D; Aroca G; Davidge ST; López-Jaramillo P
    Growth Factors; 2012 Jun; 30(3):158-66. PubMed ID: 22486210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia.
    De Vivo A; Baviera G; Giordano D; Todarello G; Corrado F; D'anna R
    Acta Obstet Gynecol Scand; 2008; 87(8):837-42. PubMed ID: 18607829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study.
    Myers JE; Kenny LC; McCowan LM; Chan EH; Dekker GA; Poston L; Simpson NA; North RA;
    BJOG; 2013 Sep; 120(10):1215-23. PubMed ID: 23906160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.
    Kim MY; Buyon JP; Guerra MM; Rana S; Zhang D; Laskin CA; Petri M; Lockshin MD; Sammaritano LR; Branch DW; Porter TF; Merrill JT; Stephenson MD; Gao Q; Karumanchi SA; Salmon JE
    Am J Obstet Gynecol; 2016 Jan; 214(1):108.e1-108.e14. PubMed ID: 26432463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal changes in maternal soluble endoglin and angiopoietin-2 in women at risk for pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Elkhouli M; Nicolaides KH
    Ultrasound Obstet Gynecol; 2014 Oct; 44(4):402-10. PubMed ID: 24913462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis.
    Kleinrouweler CE; Wiegerinck MM; Ris-Stalpers C; Bossuyt PM; van der Post JA; von Dadelszen P; Mol BW; Pajkrt E;
    BJOG; 2012 Jun; 119(7):778-87. PubMed ID: 22433027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for pre-eclampsia early in pregnancy: performance of a multivariable model combining clinical characteristics and biochemical markers.
    Giguère Y; Massé J; Thériault S; Bujold E; Lafond J; Rousseau F; Forest JC
    BJOG; 2015 Feb; 122(3):402-10. PubMed ID: 25175335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Added value of angiogenic factors for the prediction of early and late preeclampsia in the first trimester of pregnancy.
    Crovetto F; Figueras F; Triunfo S; Crispi F; Rodriguez-Sureda V; Peguero A; Dominguez C; Gratacos E
    Fetal Diagn Ther; 2014; 35(4):258-66. PubMed ID: 24714555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gestational angiogenic biomarker patterns in high risk preeclampsia groups.
    Maynard SE; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Moore Simas TA
    Am J Obstet Gynecol; 2013 Jul; 209(1):53.e1-9. PubMed ID: 23517919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia.
    Aggarwal PK; Chandel N; Jain V; Jha V
    J Hum Hypertens; 2012 Apr; 26(4):236-41. PubMed ID: 21451568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competing endogenous RNA expression profiling in pre-eclampsia identifies hsa_circ_0036877 as a potential novel blood biomarker for early pre-eclampsia.
    Hu X; Ao J; Li X; Zhang H; Wu J; Cheng W
    Clin Epigenetics; 2018; 10():48. PubMed ID: 29643944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia.
    Foidart JM; Munaut C; Chantraine F; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2010 Jun; 35(6):680-7. PubMed ID: 20205159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of urinary soluble endoglin in the diagnosis of pre-eclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio.
    Buhimschi CS; Baumbusch MA; Dulay AT; Lee S; Wehrum M; Zhao G; Bahtiyar MO; Pettker CM; Ali UA; Funai EF; Buhimschi IA
    BJOG; 2010 Feb; 117(3):321-30. PubMed ID: 19943826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased secretory sphingomyelinase activity in the first trimester of pregnancy in women later developing preeclampsia: a nested case-control study.
    Rodríguez-Sureda V; Crovetto F; Triunfo S; Sánchez O; Crispi F; Llurba E; Gratacós E; Figueras F; Domínguez C
    Biol Chem; 2016 Mar; 397(3):269-79. PubMed ID: 26756094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
    N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.